<DOC>
	<DOCNO>NCT02349386</DOCNO>
	<brief_summary>The objective clinical study evaluate safety efficacy three different dos BHR-200 ( 0.36 % transdermal estradiol gel ) compare placebo maintenance testosterone ( T ) suppression men advance androgen-sensitive prostate cancer .</brief_summary>
	<brief_title>Maintaining Suppression Testosterone With Transdermal Estradiol Gel</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , placebo-controlled , dose find study men advance androgen-sensitive prostate cancer . Patients give informed consent screen evaluation , fulfil entry criterion , randomize one 4 treatment group : 1mL , 2mL 3mL 0.36 % BHR-200 ( transdermal estradiol gel ) Placebo . Study drug initiate day schedule receive next depot GnRH agonist injection . Patients offer low-dose radiation aid prevention gynecomastia . Patients apply study drug per day . The first dose study gel applied supervision PI/designee . Subsequent dose self-administered daily patient longer chemically castrate ( testosterone level increase 50 ng/dL ) , rise baseline PSA &gt; 0.5 ng/mL observe , complete 52 week study drug administration . At conclusion study participation , patient advise resume standard care treatment supervision healthcare provider . While treatment , patient evaluate Day 1 every 2 week , first 24 week every 4 week thereafter final post-treatment follow-up visit 2 week ( +/- 1 week ) post last dose administration .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>1 . Males , Ages 18 old 2 . Body Mass Index ( BMI ) 18 35 kg/m2 ( inclusive ) 3 . Not currently hospitalize 4 . Clinical indication adenocarcinoma prostate evidence biopsy report record 5 . At present receive ADT treatment GnRH agonist least 2 month longer 36 month without interruption Note : If patient receive GnRH agonist treatment prior treatment describe 5 , must evidence period without GnRH agonist treatment minimum 2 month prior start present treatment see , example intermittent treatment regimen . 6 . Able initiate Screening procedures 2 week prior next schedule injection GnRH agonist 7 . Willing discontinue current ADT regimen duration study 8 . T level le 50 ng/dL Screening 9 . WHO/ECOG performance status 0 1 10 . Life expectancy least 1 year 11 . Adequate renal function demonstrate normal blood urea nitrogen ( BUN ) Creatinine Screening lab value 1 . History presence allergic adverse response estradiol 2 . Presence symptomatic metastatic disease , risk spinal cord compression urinary obstruction 3 . History within past 2 year deep vein thrombosis ( DVT ) , pulmonary embolism ( PE2 ) , know thrombophilic disorder ( eg.protein C , protein S , antithrombin deficiency ) , cerebrovascular accident ( CVA ) 4 . History within past 2 year myocardial infarction coronary vascular procedure ( e.g . percutaneous coronary intervention , coronary artery bypass graft ) 5 . History congestive heart failure 6 . Use investigational drug , biologic , device within 28 day prior first dose study gel 7 . Use follow known inducer inhibitor cytochrome P450 3A4 ( CYP3A4 ) : phenobarbital , carbamazepine , rifampin , erythromycin , clarithromycin , ketoconazole , itraconazole , ritonavir , St. John 's Wort preparation ( Hypericum perforatum ) , grapefruit juice 8 . Hematological parameter ( Hematocrit Hemoglobin ) outside 20 % upper low limit normal Screening 9 . Active skin rash , sunburn , skin disorder upper arm ( ) require treatment may affect skin absorption study gel 10 . Resting uncontrolled hypertension ( HTN ) ( 160/100 mmHg ) Screening 11 . Coexistent malignancy history malignancy past 5 year , exception basal and/or squamous cell carcinoma skin 12 . Any significant concurrent illness disease condition opinion Investigator might interfere patient 's ability receive treatment outline protocol might put additional risk</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>